Truist reiterates Buy on Inventiva stock ahead of phase 3 data
AI Summary
Truist reiterated a Buy rating on Inventiva ahead of the company's phase 3 data. The report provides no further information about the trial or its expected results.
Truist reiterated a Buy rating on Inventiva ahead of the company's phase 3 data. The report provides no further information about the trial or its expected results.
STAT News Health —
FreightWaves —
Investing.com —
Investing.com —
Investing.com —
Investing.com —